Interactions : אינטראקציות

4.5 Interaction with other medicinal products and other forms of interaction

No formal assessments of pharmacokinetic interactions between ARSENIC TRIOXIDE and other therapeutic medicinal products have been conducted.

Medicinal products known to cause QT/QTc interval prolongation, hypokalaemia or hypomagnesaemia 
QT/QTc prolongation is expected during treatment with arsenic trioxide, and torsade de pointes and complete heart block have been reported. Patients who are receiving, or who have received, medicinal products known to cause hypokalaemia or hypomagnesaemia, such as diuretics or amphotericin B, may be at higher risk for torsade de pointes. Caution is advised when ARSENIC TRIOXIDE S.K. 1MG/ML is co-administered with other medicinal products known to cause QT/QTc interval prolongation such as macrolide antibiotics, the antipsychotic thioridazine, or medicinal products known to cause hypokalaemia or hypomagnesaemia.
Additional information about QT prolonging medicinal agents, is provided in section 4.4.

Medicinal products known to cause hepatotoxic effects

Hepatotoxic effects may occur during the treatment with arsenic trioxide, caution is advised when ARSENIC TRIOXIDE S.K. 1MG/ML is co-administered with other medicinal products known to cause hepatotoxic effects (see sections 4.4 and 4.8).

Other antileukaemic medicinal products

The influence of ARSENIC TRIOXIDE S.K. 1MG/ML on the efficacy of other antileukaemic medicinal products is unknown.